BONE AND RENAL SAFETY OF TENOFOVIR ALAFENAMIDE ( TAF) AT 8 YEARS IN CHRONIC HBV ( CHB) PATIENTS WITH UNDERLYING RISK FACTORS FOR USE OF TENOFOVIR DISOPROXIL FUMARATE ( TDF)

被引：0
|
作者：
Buti, Maria [1 ,2 ]
Gane, Edward J. [3 ]
Agarwal, Kosh [4 ]
Wong, Grace Lai-Hung C. [5 ]
Lim, Young-Suk [6 ]
Chen, Chi-Yi [7 ]
Lim, Seng Gee [8 ]
Yatsuhashi, Hiroshi [9 ]
Fung, Scott K. [10 ]
Abramov, Frida [11 ]
Wang, Hongyuan [11 ]
Yee, Leland J. [11 ]
Flaherty, John F. [11 ]
Pan, Calvin Q. [12 ]
Marcellin, Patrick [13 ]
机构：
[1] Hosp Univ Vall Dhebron, Barcelona, Spain
[2] Ciberehd Inst Carlos III, Madrid, Spain
[3] Univ Auckland, Auckland, New Zealand
[4] Kings Coll Hosp London, Inst Liver Studies, London, England
[5] Chinese Univ Hong Kong, MDAC, Hong Kong, Peoples R China
[6] Univ Ulsan, Coll Med, Asan Med Ctr, Seoul, South Korea
[7] Chiayi Christian Hosp, Chiayi, Taiwan
[8] Natl Univ Hlth Syst, Singapore, Singapore
[9] Natl Hosp Org Nagasaki Med Ctr, Clin Res Ctr, Nagasaki, Japan
[10] Univ Toronto, Dept Med, Toronto, ON, Canada
[11] Gilead Sci Inc, Foster City, CA 94404 USA
[12] NYU, NYU Langone Hlth, Grossman Sch Med, New York, NY USA
[13] Univ Paris, Hop Beaujon, AP HP, Paris, France
来源：
HEPATOLOGY | 2023年 / 78卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1405C
引用
收藏
页码：S507 / S509
页数：3
相关论文
共 50 条
  • [21] RENAL AND BONE SAFETY OF TENOFOVIR ALAFENAMIDE VS TENOFOVIR DISOPROXIL FUMARATE
    Post, Frank
    Sax, Paul
    Saag, Michael
    Yin, Michael
    Oka, Shinichi
    Koenig, Ellen
    Trottier, Benoit
    Andrade, Jaime
    Cao, Huyen
    Fordyce, Marshall
    SEXUALLY TRANSMITTED INFECTIONS, 2015, 91 : A48 - +
  • [22] Minimal Changes in Urine Markers of Tubular Dysfunction in CHB Patients Receiving Tenofovir alafenamide (TAF) compared with Tenofovir Disoproxil Fumarate (TDF)
    Lim, Young-Suk
    Ide, Tatsuya
    Strasser, Simone I.
    Yoon, Ki Tae
    Paik, Seung Woon
    Flaherty, John F.
    Kim, Kyungpil
    Gaggar, Anuj
    Subramanian, Mani
    Mangia, Alessandra
    Simon, Krzysztof
    Kwan, Peter
    Gane, Edward J.
    HEPATOLOGY, 2016, 64 : 940A - 940A
  • [23] Safety and efficacy at 1 year after switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide in patients with chronic hepatitis B and risk factors for TDF use
    Gane, E.
    Seto, W. K.
    Janssen, H.
    Caruntu, F. A.
    Kim, H. J.
    Abdurakhmanov, D.
    Nishiguchi, S.
    Andrzej, H.
    Bae, H.
    Mo, S.
    Suri, V.
    Gaggar, A.
    Flaherty, J. F.
    Kao, J-H
    Brunetto, M.
    Buti Ferret, M.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2018, 33 : 42 - 43
  • [24] Safety and efficacy at 1 year after switching from Tenofovir Disoproxil Fumurate to Tenofovir Alafenamide in chronic HBV patients with risk factors for TDF use
    Gane, E.
    Seto, W-K.
    Janssen, H.
    Caruntu, F. A.
    Kim, H. J.
    Abdurakhmanov, D.
    Nishiguchi, S.
    Andrzej, H.
    Bae, H.
    Mo, S.
    Suri, V.
    Gaggar, A.
    Flaherty, J. F.
    Kao, J-H.
    Brunetto, M.
    Ferret, M. B.
    JOURNAL OF HEPATOLOGY, 2018, 68 : S87 - S87
  • [25] Improved Renal Laboratory Parameters In CHB Patients Treated With TAF Compared With Tenofovir Disoproxil Fumarate (TDF)
    Agarwal, Kosh
    Furusyo, Norihiro
    Byun, Kwan Soo
    Hwang, Jaeseok
    Flaherty, John F.
    Kim, Kyungpil
    Gaggar, Anuj
    Subramanian, Mani
    Jablkowski, Maciej S.
    Yakovlev, Alexey A.
    Trinh, Huy N.
    Buti, Maria
    HEPATOLOGY, 2016, 64 : 910A - 910A
  • [26] IMPACT OF COADMINISTRATION WITHOUT OR WITH FOOD ON THE 96-WEEK EFFICACY AND SAFETY OF TENOFOVIR ALAFENAMIDE (TAF) IN VIRALLY SUPPRESSED CHRONIC HBV PATIENTS SWITCHED FROM TENOFOVIR DISOPROXIL FUMARATE (TDF) TO TAF
    Kao, Jia-Horng
    Chuang, Wan-Long
    Chen, Chi-Yi
    Ahn, Sang Hoon
    Fung, Scott K.
    Elkhashab, Magdy
    Hann, Hie-Won L.
    Ravendhran, Natarajan
    Nguyen, Tuan T.
    Tan, Susanna
    Flaherty, John F.
    Gagger, Anuj
    Gao, Bing
    Brainard, Diana M.
    Phan, Charles G.
    Lim, Young-Suk
    Ferret, Maria Asuncion Buti
    Lampertico, Pietro
    HEPATOLOGY, 2020, 72 : 484A - 484A
  • [27] EFFICACY AND SAFETY OF TENOFOVIR ALAFENAMIDE (TAF) VS TENOFOVIR DISOPROXIL FUMARATE (TDF) IN EAST ASIAN CHRONIC HEPATITIS B PATIENTS FOLLOWING 5-YEARS OF TREATMENT
    Wong, Grace Lai Hung
    Gane, Edward
    Pan, Calvin
    Lim, Young-Suk
    Fung, Scott
    Izumi, Namiki
    Ma, Mang
    Chan, Carol Yee Kwan
    Shalimar, Dr
    Buti, Maria
    GUT, 2021, 70 : A76 - A76
  • [28] A phase 3 study of tenofovir alafenamide (TAF) compared with tenofovir disoproxil fumarate (TDF) in patients with HBeAg-negative, chronic hepatitis B (CHB): Week 48 efficacy and safety results
    Cheng, W.
    Pianko, S.
    Thompson, A.
    Buti, M.
    Gane, E.
    Seto, W. K.
    Chan, H. L. Y.
    Chuang, W-L
    Stepanova, T.
    Hui, A-J
    Lim, Y-S
    Mehta, R.
    Janssen, H.
    Acharya, S. K.
    Flaherty, J. F.
    Massetto, B.
    Cathcart, A.
    Dinh, P.
    Subramanian, G. M.
    Mchutchison, J. G.
    Pan, C.
    Brunetto, M.
    Izumi, N.
    Marcellin, P.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2016, 31 : 68 - 69
  • [29] TENOFOVIR ALAFENAMIDE (TAF) COMPARED WITH TENOFOVIR DISOPROXIL FUMARATE (TDF) IN PATIENTS WITH CHRONIC HBV: WEEK 96 EFFICACY AND SAFETY RESULTS IN CHINESE PATIENTS ENROLLED IN 2 GLOBAL PHASE 3 STUDIES
    Chan, Henry Lik-Yuen
    Seto, Wai Kay
    Fung, Scott
    Hou, Jinlin
    Pan, Calvin
    Chuang, Wan-Long
    Chang, Ting-Tsung
    Hui, Aric-Josun
    Chen, Chi-Yi
    Tsang, Tak Yin Owen
    Yang, Jenny
    Flaherty, John
    Gaggar, Anuj
    Mo, Shuyuan
    Kao, Jia-Horng
    GUT, 2018, 67 : A302 - A302
  • [30] A phase 3 study comparing tenofovir alafenamide (TAF) to tenofovir disoproxil fumarate (TDF) in patients with HBeAg-positive, chronic hepatitis B (CHB): efficacy and safety results at week 96
    Agarwal, K.
    Fung, S.
    Seto, W. K.
    Lim, Y. S.
    Gane, E.
    Janssen, H. L.
    Sharma, M.
    Chuang, W. L.
    Bae, H.
    Yoon, K. T.
    Flaherty, J. F.
    Lau, A.
    Gaggar, A.
    Suri, V.
    Cathcart, A.
    Lin, L.
    Subramanian, G. M.
    Shalimar
    Furusyo, N.
    Buti, M.
    Chan, H. L.
    JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S478 - S478
12345